Lauren Santye, Assistant Editor

Frontotemporal dementia affects 50,000 to 60,000 patients in the United States.

There are currently no treatments deemed effective in slowing down the progression of FTD.

Low oxygen conditions encourage some cancer stem cells to multiply.

Rare effective antibodies taken from HIV patients serve as guides to reverse engineer optimal vaccine candidates.

Dupilumab shows clearance of skin lesions in most cases.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Growing out-of-pockets costs associated with reduced utilization of specialty medications.

Only 20% of lung cancer patients show a response to current immunotherapeutic antibodies.

Lipid lowering drug bococizumab is administered by a pre-filled pen.

Guide RNA shows promise eliminating HIV from the DNA of CD4 T cells.

Experimental drug bococizumab could fill the unmet needs of patients at risk for cardiovascular disease.

Study finds that manufacturers need to develop a new approach to engaging oncologists.

Statin-intolerant patients with muscle-related side effects had a greater reduction in low-density lipoprotein cholesterol from treatment with Repatha.

PCSK9 inhibitor shows promise for statin-intolerant patients with muscle-related side effects.

Humira shows promise for pediatric Crohn’s disease patients who are intolerant to or had an inadequate response to conventional therapy.

Evacetrapib found to double levels of good cholesterol and lower bad cholesterol.

People from poor or middle-income households with conditions such as diabetes or asthma face greater risk for serious mental illness.

Many physicians prescribe multi-drug tuberculosis regimens in patients with HIV as a precaution.

Tuberculosis is difficult to detect in patients with HIV.

Top stories of the day from across the health care landscape.

New treatment option emerges for pediatric Crohn’s disease patients who are intolerant to or had an inadequate response to conventional therapy.

Tofacitinib is an oral Janus kinase inhibitor that improves the signs and symptoms of psoriatic arthritis.

The oral Janus kinase inhibitor tofacitinib treats adults with active psoriatic arthritis (PsA).

Automated pharmacies are confronted with growing demands for prescription drug fills.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

SAMMSON gene thought to play an important role in the etiology of melanoma.

Combining drug trametinib with a superagonist can stimulate activity while preserving the cancer-blocking effects of the treatment.

People with difficulty repairing damaged DNA develop diabetes more rapidly when beta cells are met with cellular stress.

Plant produces compounds that treat cancer, arrhythmia, and other medical problems.